The utility of plasma p-tau217 to detect brain amyloid beta pathology (Aβ+) was studied in an Asian cohort with concomitant cerebrovascular disease Plasma tau phosphorylated at threonine 217 (p-tau217) showed superior utility in detecting Aβ+ compared to neuroimaging measures, clinical workup, or other blood biomarkers including p-tau181, glial fibrillary protein (GFAP), and Aβ Higher plasma p-tau217 correlated with faster cognitive decline Plasma p-tau217 shows promise as an Alzheimer's disease (AD) diagnostic and prognostic biomarker in diverse populations.
Authors: Joyce R. Chong, Saima Hilal, Boon Yeow Tan, Narayanaswamy Venketasubramanian, Michael Schöll, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton, Christopher Chen, Mitchell K.P. Lai
DOI: https://doi.org/10.1002/alz.14502
Publish Year: 2025
